Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Progenics second-quarter total revenue decreases to $2.3 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the second quarter and six months ended June 30, 2010.

9 Aug 2010

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today the company received CE Mark for AdVance XP. The device is the latest generation of AMS' AdVance sling, a minimally invasive implant for the treatment of male stress urinary incontinence (SUI).

9 Aug 2010

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2010 and provided a business update.

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has issued a positive opinion for RELISTOR (methylnaltrexone bromide) subcutaneous injection in pre-filled syringes.

7 Aug 2010

Surgery offers high survival rate for prostate cancer patients: Study

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.

7 Aug 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010.

7 Aug 2010

BCF publishes two new patient publications

The Bone and Cancer Foundation is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma.

7 Aug 2010

New laser technology for robotic prostate cancer surgery

One of the challenges of prostate cancer surgery is removing the cancer-affected gland without side effects. The procedure is estimated to cause long-term sexual dysfunction in half of men.Now, new published research by urologic surgeons at NewYork-Presbyterian Hospital/Columbia University Medical Center presents evidence that a new laser technology used with robotic prostate cancer surgery may reduce the risk of damaging the crucial nerves necessary for erections and urinary continence.

6 Aug 2010

Researchers recommends robotic prostatectomy over traditional open surgery method

While sharp debate continues among medical professionals as to whether a radical prostatectomy performed with the assistance of a robotic device is more beneficial than the traditional open surgery method, research just published by investigators at The Cancer Institute of New Jersey (CINJ) shows new evidence supporting the safety of the robotic procedure - including what is believed to be one of the lowest complication rates to date. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Aug 2010

Patheon, Dendreon announce signing of technology transfer agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.

6 Aug 2010

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

FDA clears iCAD's VeraLook computer-aided detection product for virtual colonoscopy

The U.S. Food and Drug Administration has given clearance to VeraLook™, iCAD's computer-aided detection product used in the interpretation of virtual colonoscopy exams. iCAD is an industry-leading provider of advanced image analysis solutions for the early detection of cancer.

5 Aug 2010

Detection of Alzheimer's before symptoms occur

Research is on to detect the dreaded Alzheimer's disease even before any symptoms occur. In a newly proposed diagnostic criteria developed by experts from the National Institute on Aging and the Alzheimer's Association three stages of the disease viz. pre-clinical Alzheimer's, mild cognitive impairment and Alzheimer's dementia are described.

4 Aug 2010

GenSpera acquires patent application for medical imaging technology

GenSpera, Inc. announced that it has acquired a patent application from the Johns Hopkins University and the University of Copenhagen for technology relating to medical imaging. The technology incorporates derivatives of thapsigargin, the active ingredient in GenSpera's therapeutics program, coupled with its patented tumor-targeted peptides, to create cancer-specific imaging compounds.

4 Aug 2010

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Biotechnology company MabCure, Inc. today announced the company has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the U.S. Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure's tumor-specific monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent) and distinguished it from benign tumors of the ovaries or healthy blood obtained from men and women.

4 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Progenics second-quarter total revenue decreases to $2.3 million

AMS AdVance XP sling for male stress urinary incontinence receives CE Mark

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

GTx second-quarter net loss increases to $12.9 million

ESMO Congress provides forum for presentation of new research on treatment of cancer

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Surgery offers high survival rate for prostate cancer patients: Study

OncoGenex reports net income in second-quarter 2010 against loss last year

BCF publishes two new patient publications

New laser technology for robotic prostate cancer surgery

Researchers recommends robotic prostatectomy over traditional open surgery method

Patheon, Dendreon announce signing of technology transfer agreement

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

FDA clears iCAD's VeraLook computer-aided detection product for virtual colonoscopy

Detection of Alzheimer's before symptoms occur

GenSpera acquires patent application for medical imaging technology

MabCure files provisional patent application for ovarian cancer diagnostic antibodies

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in